Halozyme Therapeutics HALO Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's accounts payable?
- Halozyme Therapeutics (HALO) reported accounts payable of $14.1M in Q1 2026.
- How has Halozyme Therapeutics's accounts payable changed year-over-year?
- Halozyme Therapeutics's accounts payable decreased by 29.8% year-over-year, from $20.07M to $14.1M.
- What is the long-term trend for Halozyme Therapeutics's accounts payable?
- Over 5 years (2020 to 2025), Halozyme Therapeutics's accounts payable has grown at a 61.1% compound annual growth rate (CAGR), from $1.93M to $20.9M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.